var data={"title":"Hydroxyurea (hydroxycarbamide): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydroxyurea (hydroxycarbamide): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6345?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydroxyurea (hydroxycarbamide): Patient drug information&quot;</a> and <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydroxyurea (hydroxycarbamide): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708910\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression (Droxia, Siklos):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydroxyurea may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary malignancy (Droxia, Siklos):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181021\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Droxia;</li>\n      <li>Hydrea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181022\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hydrea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181060\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181025\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be based on ideal or actual body weight, whichever is less (per manufacturer). Prophylactic administration of folic acid is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia (Hydrea):</b> Oral: Initial: 40 mg/kg/day (reduce initial dose for thrombocytopenia); reduce dose to 20 mg/kg/day if WBC count &lt;2,000/mm<sup>3</sup>. Further individualize dose based on WBC counts (Hehlmann 1993). Hydroxyurea may be used for short-term therapy of elevated WBC counts prior to initiating a TKI (Bacarrini 2013, Cortes 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer</b>\n      <b> (Hydrea):</b> Oral (individualize treatment/regimen based on tumor type, response, and current clinical practice standards): 1,000 mg every 12 hours for 11 doses per cycle, in combination with continuous infusion fluorouracil and radiation therapy (Garden 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sickle cell anemia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Droxia:</i> Initial: 15 mg/kg/day as a single daily dose. Monitor blood counts every 2 weeks; if blood counts are in an acceptable range, may increase by 5 mg/kg/day every 12 weeks until the maximum tolerated dose of 35 mg/kg/day is achieved or the dose that does not produce toxic effects over 24 consecutive weeks (do not increase dose if blood counts are between acceptable and toxic ranges). If toxicity occurs, withhold treatment until the bone marrow recovers, then restart with a dose reduction of 2.5 mg/kg/day; if no toxicity occurs over the next 12 weeks, then the subsequent dose may be increased by 2.5 mg/kg/day every 12 weeks to a maximum tolerated dose (dose that does not produce hematologic toxicity for 24 consecutive weeks). If hematologic toxicity recurs a second time at a specific dose, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acceptable hematologic ranges:</i> Neutrophils &ge;2,500/mm<sup>3</sup>; platelets &ge;95,000/mm<sup>3</sup>; hemoglobin &gt;5.3 g/dL; and reticulocytes &ge;95,000/mm<sup>3</sup> if hemoglobin is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Toxic hematologic ranges:</i> Neutrophils &lt;2,000/mm<sup>3</sup>; platelets &lt;80,000/mm<sup>3</sup>; hemoglobin &lt;4.5 g/dL; and reticulocytes &lt;80,000/mm<sup>3</sup> if hemoglobin is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Siklos:</i> Initial: 20 mg/kg/day as a single daily dose. Monitor blood counts every 2 weeks; if blood counts are in an acceptable range, may increase by 5 mg/kg/day every 8 weeks or if a painful crisis occurs until mild myelosuppression (ANC 2,000 to 4,000/mm<sup>3</sup>) is achieved, or up to a maximum dose of 35 mg/kg/day. If blood counts are in a toxic range, discontinue until hematologic recovery. Following hematologic recovery, restart with the dose reduced by 5 mg/kg/day; may titrate dose up or down every 8 weeks in 5 mg/kg/day increments, seeking a stable dose with no hematologic toxicity for 24 weeks. Discontinue permanently if hematologic toxicity develops twice.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acceptable hematologic ranges:</i> Neutrophils &ge;2,000/mm<sup>3</sup>; platelets &ge;80,000/mm<sup>3</sup>; hemoglobin &gt;5.3 g/dL; and reticulocytes &ge;80,000/mm<sup>3</sup> if hemoglobin is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Toxic hematologic ranges:</i> Neutrophils &lt;2,000/mm<sup>3</sup> (neutrophil limit of 1,250/mm<sup>3</sup> may be acceptable in younger patients with lower baseline counts); platelets &lt;80,000/mm<sup>3</sup>; hemoglobin &lt;4.5 g/dL; and reticulocytes &lt;80,000/mm<sup>3</sup> if hemoglobin is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Calculate rounded doses to the nearest 50 or 100 mg strength.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> A clinical response to treatment may take 3 to 6 months; a 6-month trial of the maximum tolerated dose is recommended prior to considering discontinuation due to treatment failure. Effectiveness of hydroxyurea depends upon daily dosing adherence. For patients who have a clinical response, long-term hydroxyurea therapy is indicated (NHLBI 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute myeloid leukemia (AML), cytoreduction (off-label use):</b> Oral: 50 to 100 mg/kg/day until WBC &lt;100,000/mm<sup>3</sup> (Grund 1977) <b>or</b> 50 to 60 mg/kg/day until WBC &lt;10,000 to 20,000/mm<sup>3</sup> (Dohner 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential thrombocythemia, high-risk (off-label use):</b> Oral: 500 to 1000 mg daily; adjust dose to maintain platelets &lt;400,000/mm<sup>3</sup> (Harrison 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypereosinophilic syndrome (off-label use):</b> Oral: 1,000 to 3,000 mg/day (Klion 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningioma (off-label use):</b> Oral: 20 mg/kg once daily (Newton 2000; Rosenthal 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycythemia vera, high-risk (off-label use):</b> Oral: 15 to 20 mg/kg/day (Finazzi 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181043\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydroxyurea (hydroxycarbamide): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be based on ideal or actual body weight, whichever is less (per manufacturer). Prophylactic administration of folic acid is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sickle cell anemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months and Children &lt;2 years (off-label population): Oral: 20 mg/kg/dose once daily; increase by 5 mg/kg/<b>day</b> every 8 weeks until mild myelosuppression (target ANC 2,000 to 4,000/mm<sup>3 </sup>[a lower ANC limit of 1,500/mm<sup>3</sup> has been used in some studies]) is achieved; maximum dose: 35 mg/kg/<b>day </b>(Hankins 2005; NHLBI 2014; Strouse 2012; Thornburg 2009; Wang 2001; Wang 2011); an initial starting dose of 15 mg/kg/dose once daily has also been studied (Kinney 1999; Zimmerman 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If myelosuppression occurs (platelets &lt;80,000/mm<sup>3</sup>, neutrophils &lt;2,000/mm<sup>3</sup>; younger patients with lower baseline counts may safely tolerate ANC down to 1,250/mm<sup>3</sup>), hold therapy until counts recover (monitor weekly); reinitiate at a dose 5 mg/kg/<b>day</b> lower than the dose given prior to onset of cytopenias (NHLBI 2014); some have recommended reinitiating at a dose 2.5 mg/kg/<b>day</b> lower (Hankins 2005; Wang 2001; Wang 2011; Zimmerman 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> A clinical response to treatment may take 3 to 6 months; a 6-month trial of the maximum tolerated dose is recommended prior to considering discontinuation due to treatment failure. Effectiveness of hydroxyurea depends upon daily dosing adherence. For patients who have a clinical response, long-term hydroxyurea therapy is indicated (NHLBI 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: <i>Siklos:</i> Initial: 20 mg/kg/day as a single daily dose. Monitor blood counts every 2 weeks; if blood counts are in an acceptable range, may increase by 5 mg/kg/day every 8 weeks or if a painful crisis occurs until mild myelosuppression (ANC 2,000 to 4,000/mm<sup>3</sup>) is achieved, or up to a maximum dose of 35 mg/kg/day. If blood counts are in a toxic range, discontinue until hematologic recovery. Following hematologic recovery, restart with the dose reduced by 5 mg/kg/day; may titrate dose up or down every 8 weeks in 5 mg/kg/day increments, seeking a stable dose with no hematologic toxicity for 24 weeks. Discontinue permanently if hematologic toxicity develops twice. An initial starting dose of 15 mg/kg/dose once daily has also been studied (Kinney 1999, Zimmerman 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acceptable hematologic ranges:</i> Neutrophils &ge;2,000/mm<sup>3</sup>; platelets &ge;80,000/mm<sup>3</sup>; hemoglobin &gt;5.3 g/dL; and reticulocytes &ge;80,000/mm<sup>3</sup> if hemoglobin is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Toxic hematologic ranges:</i> Neutrophils &lt;2,000/mm<sup>3</sup> (neutrophil limit of 1,250/mm<sup>3</sup> may be acceptable in younger patients with lower baseline counts); platelets &lt;80,000/mm<sup>3</sup>; hemoglobin &lt;4.5 g/dL; and reticulocytes &lt;80,000/mm<sup>3</sup> if hemoglobin is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Calculate rounded doses to the nearest 50 or 100 mg strength.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> A clinical response to treatment may take 3 to 6 months; a 6-month trial of the maximum tolerated dose is recommended prior to considering discontinuation due to treatment failure. Effectiveness of hydroxyurea depends upon daily dosing adherence. For patients who have a clinical response, long-term hydroxyurea therapy is indicated (NHLBI 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181026\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. May require lower doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181027\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CML, head and neck cancer (manufacturer's labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: No dosage adjustment (of initial dose) necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;60 mL/minute: Reduce initial dose by 50%; titrate to response/avoidance of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): Reduce initial dose by 50% (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sickle cell anemia:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Droxia:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: No dosage adjustment (of initial dose) necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;60 mL/minute: Reduce initial dose by 50% to 7.5 mg/kg/day (Yan 2005); titrate to response/avoidance of toxicity (refer to usual dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD: Reduce initial dose by 50% to 7.5 mg/kg/dose (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Siklos:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: No dosage adjustment (of initial dose) necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;60 mL/minute: Reduce initial dose by 50% to 10 mg/kg/day; titrate to response/avoidance of toxicity (refer to usual dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD: Reduce initial dose by 50% to 10 mg/kg/day; titrate to response/avoidance of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NHLBI 2014: Adults: Chronic kidney disease: Initial 5 to 10 mg/kg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5528419\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; closely monitor for bone marrow toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20500209\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer (solid tumors):</i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012). <b>Note:</b> The manufacturer recommends dosing based on ideal or actual body weight, whichever is less.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15598381\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cutaneous vasculitic ulcerations: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pancreatitis: Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic toxicity: CML, head and neck cancer: Do not initiate therapy if bone marrow function is markedly reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sickle cell anemia:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Droxia</i>: Neutrophils &lt;2,000/mm<sup>3</sup>, platelets &lt;80,000/mm<sup>3</sup>, hemoglobin &lt;4.5 g/dL, or reticulocytes &lt;80,000/mm<sup>3</sup> with hemoglobin &lt;9 g/dL: Interrupt treatment; following recovery, may resume with a dose reduction of 2.5 mg/kg/day. Hydroxyurea may then be titrated up or down every 12 weeks in 2.5 mg/kg/day increments until the patient is at a stable dosage that does not result in hematologic toxicity for 24 weeks. If hematologic toxicity recurs a second time at a specific dose, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Siklos</i>: Neutrophils &lt;2,000/mm<sup>3 </sup>(neutrophil limit of 1,250/mm<sup>3</sup> may be acceptable in younger patients with lower baseline counts), platelets &lt;80,000/mm<sup>3</sup>, hemoglobin &lt;4.5 g/dL, and reticulocytes &lt;80,000/mm<sup>3</sup> with hemoglobin &lt;9 g/dL: Interrupt treatment; following recovery, may resume with a dose reduction of 5 mg/kg/day. Hydroxyurea may then be titrated up or down every 8 weeks in 5 mg/kg/day increments until the patient is at a stable dosage that does not result in hematologic toxicity for 24 weeks. If hematologic toxicity recurs a second time at a specific dose, discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180998\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Droxia: 200 mg, 300 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Droxia: 400 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hydrea: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180983\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50964559\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Droxia: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016295s049s050lbl.pdf#page=15&amp;token=xp3qlqdSFlgKdLm+woZmjMMUJILPQqwrYf7RZv52lv9ydBTr+cGxL6KP/64y53jBGgv1rCUmlEkS54I1aAJBD7TVC1tC7LfRdgmBj6IvVtkLqjnIiy0Zfy1Z8f8JnX/P&amp;TOPIC_ID=8543\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016295s049s050lbl.pdf#page=15</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Siklos: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf#page=17&amp;token=ieHGobpnwoqBZaCeBlVs4FSL8UsZPIYwreEyyOq7JbmSbNqnqTQVajJDnPokwNqc5mJ5I0uusKDQbxOl1bzwaqmR/G8yXj9tFyOhHnPdsz1C2lg5C2if1ZL4OfXLhnVf&amp;TOPIC_ID=8543\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf#page=17</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181002\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer at the same time each day. Swallow whole, do not open capsules.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siklos: Administer with water. If unable to swallow tablets whole, may disperse immediately before use in a small amount of water in a teaspoon (add tablet to spoon, add water; tablet dissolves in ~1 minute; administer immediately); drink an additional glass of water after administering the dose. The 1,000 mg tablets are scored with 3 lines to enable splitting into 4 parts; wear gloves and use a damp paper towel surface to break scored tablets (properly dispose of used gloves and paper towel). Do not split the 100 mg tablet into smaller parts.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Impervious gloves should be worn when handling bottles containing hydroxyurea or when handling/administering intact capsules/tablets. Wash hands with soap and water before and after contact with hydroxyurea. Avoid exposure to crushed capsules/tablets or open capsules. If skin contact occurs, immediately wash the affected area thoroughly with soap and water. If eye(s) contact occurs, the affected area should be flushed thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If powder from the capsules or tablets is spilled, immediately wipe it up with a damp disposable towel and discard (along with the empty capsules) in a closed container, such as a plastic bag. The spill areas should then be cleaned using a detergent solution followed by clean water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132627\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181001\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia, resistant (Hydrea):</b> Treatment of resistant chronic myeloid leukemia (CML)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer (Hydrea):</b> Management (in combination with chemoradiation therapy) of locally advanced squamous cell head and neck cancer (excluding lip cancer)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sickle cell anemia (Droxia, Siklos):</b> Management of sickle cell anemia (to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with recurrent moderate to severe painful crises) in adults (Droxia) or in children &ge;2 years, adolescents, and adults (Siklos)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474843\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myeloid leukemia, cytoreduction; Essential thrombocythemia, high-risk; Hypereosinophilic syndrome; Meningioma; Polycythemia vera, high-risk</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181070\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydrea may be confused with Lyrica</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydroxyurea may be confused with hydroxychloroquine, hydrOXYzine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydrea [US, Canada, and multiple international markets] may be confused with Hydra brand name for isoniazid [Japan]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180990\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypersensitivity angiitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, disorientation, dizziness, drowsiness (dose-related), hallucination, headache, malaise, peripheral neuropathy (HIV-infected patients), seizure, vasculitic ulcerations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Eczema (infants and children 9 to 18 months: 13% [Thornburg 2012]), leg ulcer (7% [Hern&aacute;ndez-Boluda 2011]), dermal ulcer (3% [Antonioli 2012]), nail discoloration (2% [Randi 2005]), alopecia (infrequent, [Hern&aacute;ndez-Boluda 2011]), changes in nails (infrequent, [Hern&aacute;ndez-Boluda 2011]), hyperpigmentation (infrequent, [Hern&aacute;ndez-Boluda 2011]), atrophy of nail, dermatomyositis-like skin changes, desquamation, erythema (peripheral), facial erythema, gangrene of skin or other tissue, maculopapular rash, papule (violet), skin atrophy, skin carcinoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased uric acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Acute mucocutaneous toxicity (5% [Hern&aacute;ndez-Boluda 2011]), diarrhea (infrequent, [Antonioli 2012]), gastric distress (infrequent, [Antonioli 2012]), nausea (infrequent, [Antonioli 2012]), oral mucosa ulcer (infrequent, [Hern&aacute;ndez-Boluda 2011]), anorexia, BSP abnormality (retention), constipation, gastrointestinal irritation (potentiated with radiation therapy), mucositis (potentiated with radiation therapy), pancreatitis (HIV-infected patients), stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukemia (4% [Hern&aacute;ndez-Boluda 2011]; secondary; long-term use), leukopenia (2% [Hern&aacute;ndez-Boluda 2011]), bone marrow depression (neutropenia [common], thrombocytopenia; hematologic recovery: within 2 weeks); abnormal erythropoiesis (megaloblastic; self-limiting), macrocytosis (MCV &gt;97: 42% [Randi 2005]), reticulocytopenia (infants and children 9 to 18 months [Wang 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic failure (HIV-infected patients), hepatotoxicity, increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Panniculitis (Antonioli 2012), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal:  Increased blood urea nitrogen, increased serum creatinine, renal tubular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma (infants and children 9 to 18 months: 9% [Thornburg 2012]), dyspnea, pulmonary fibrosis (rare), pulmonary infiltrates (diffuse, rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Actinic keratosis (Antonioli 2012), azoospermia, basal cell carcinoma (Antonioli 2012), cholestasis, hepatitis, hyperkeratosis (Antonioli 2012), lesion (dyschromic [Antonioli 2012]), malignant neoplasm (Wong 2014), mucous membrane lesion (Antonioli 2012), oligospermia, pneumonitis (Antonioli 2012), squamous cell carcinoma (Antonioli 2012), tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181005\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity to hydroxyurea or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe bone marrow depression (eg, leukopenia [&lt;2,500/mm<sup>3</sup>], thrombocytopenia [&lt;100,000/mm<sup>3</sup>], or severe anemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180987\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression:<b> [US Boxed Warning]: Hydroxyurea may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary.</b> Leukopenia and neutropenia commonly occur (thrombocytopenia and anemia are less common); leukopenia/neutropenia occur first. Severe or life-threatening myelosuppression may occur at the recommended initial dose. Hematologic toxicity is reversible (rapid) with treatment interruption; after treatment interruption, resume therapy at a lower dose. Use with caution in patients with a history of prior chemotherapy or radiation therapy; myelosuppression is more common. Correct severe anemia prior to initiating treatment. Do not initiate therapy if bone marrow function is markedly reduced. Pediatric patients are at increased risk for myelosuppression at the time of dosage adjustments due to changes in body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous vasculitic toxicities: Vasculitic ulcerations and gangrene have been reported in patients with myeloproliferative disorders during hydroxyurea treatment, most often in patients with a history of or receiving concurrent interferon therapy. Discontinue hydroxyurea (or reduce the dose) and consider alternate cytoreductive therapy if cutaneous vasculitic toxicity develops. Ulcers may rarely be caused by leukocytoclastic vasculitis. Avoid use in patients with leg ulcer wounds.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Drug-induced fever has been reported (with cardiovascular, dermatologic, GI, hepatic, musculoskeletal, or pulmonary manifestations); may require hospitalization. The onset is usually within 6 weeks of treatment initiation and resolves with discontinuation. Fever usually recurred within 24 hours with re-challenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macrocytosis: Self-limiting macrocytosis may be seen early in treatment (may resemble pernicious anemia, but is unrelated to vitamin B<sub>12</sub> or folic acid deficiency). May mask diagnosis of pernicious anemia. Prophylactic folic acid supplementation is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: <b>[US Boxed Warning]: Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies.</b> Treatment of myeloproliferative disorders (eg, polycythemia vera, thrombocythemia) with long-term hydroxyurea is associated with secondary leukemia; it is unknown if this is drug-related or disease-related. Skin cancer has been reported with long-term hydroxyurea use. Monitor for signs/symptoms of secondary malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Hyperuricemia may occur with antineoplastic treatment; adequate hydration and initiation or dosage adjustment of uricosuric agents (eg, allopurinol) may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV-infected patients: Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred when hydroxyurea was administered with antiretroviral medications, including didanosine and stavudine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may require dose reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concurrent drug therapy issues: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: May be more sensitive to the effects of hydroxyurea; may require lower doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Patients with a history of radiation therapy are at risk for exacerbation of post irradiation erythema and myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Avoid use of live vaccines during hydroxyurea therapy. Concomitant use may potentiate viral replication and may possibly increase vaccine adverse reactions due to suppression of normal defense mechanisms by hydroxyurea and result in severe infections. The antibody response to vaccines may be decreased. Consider consultation with a specialist if immunization with a live vaccine is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299494\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180992\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8543&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Hydroxyurea may enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stavudine: Hydroxyurea may enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181009\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. Based on its mechanism of action, hydroxyurea may cause fetal harm if administered during pregnancy. Women of reproductive potential should be advised to avoid becoming pregnant during treatment (verify pregnancy status prior to starting hydroxyurea therapy) and should use effective contraception during and for at least 6 months after completion of therapy. Hydroxyurea use may damage spermatozoa and testicular tissue; males with female partners of reproductive potential should use effective contraception during and for at least 6 months (Siklos) or 1 year (Droxia, Hydrea) after therapy. Azoospermia or oligospermia (sometimes reversible) has been observed in male patients; counsel males of reproductive potential about sperm banking prior to therapy initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2527156\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Hydroxyurea is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3518430\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Supplemental administration of folic acid is recommended; hydroxyurea may mask development of folic acid deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180996\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (once weekly for antineoplastic indications; every 2 weeks initially for sickle cell anemia), renal function and liver function tests, serum uric acid; hemoglobin F levels (sickle cell disease; every 3 to 4 months); pregnancy status prior to therapy initiation in women of reproductive potential; monitor for cutaneous toxicities</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Sickle cell disease: Monitor for toxicity every 2 weeks during dose escalation (neutrophils, platelets, hemoglobin, reticulocytes) (manufacturer's labeling) or at least every 4 weeks when adjusting the dose (CBC with WBC differential, reticulocytes) [NHLBI 2014]). Once on a stable dose, may monitor CBC with differential, reticulocyte count and platelets every 2 to 3 months (NHLBI 2014). Monitor RBC, MCV (mean corpuscular volume) and HbF (fetal hemoglobin) levels for evidence of consistent or progressive laboratory response (NHLBI 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180986\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hydroxyurea is an antimetabolite that selectively inhibits ribonucleoside diphosphate reductase, preventing the conversion of ribonucleotides to deoxyribonucleotides, halting the cell cycle at the G1/S phase and therefore has radiation sensitizing activity by maintaining cells in the G<sub>1</sub> phase and interfering with DNA repair. In sickle cell anemia, hydroxyurea increases red blood cell (RBC) hemoglobin F levels, RBC water content, deformability of sickled cells, and alters adhesion of RBCs to endothelium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181004\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> In pediatric patients, large interpatient variability and phenotypic differences have been reported (Ware 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Sickle cell anemia: Fetal hemoglobin increase: 4 to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Readily absorbed  (&ge;80%); relatively rapid (Rodriguez 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes widely into tissues (including into the brain); estimated volume of distribution approximates total body water (Gwilt 1998); concentrates in leukocytes and erythrocytes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Children: ~12 L (range: 2.5 to 52) (Ware 2011); Adults: ~20 L/m<sup>2</sup> (Rodriguez 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Up to 60% via hepatic metabolism and urease found in intestinal bacteria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~100% (Rodriguez 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 75% to 80% bound to serum proteins (Gwilt 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1.9 to 3.9 hours (Gwilt 1998); Children: Sickle cell anemia: 1.7 hours (range: 0.7 to 3 hours) (Ware 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Children: &quot;Fast&quot; phenotype: 15 to 30 minutes; &quot;Slow&quot; phenotype: 60 to 120 minutes (Ware 2011); Adults: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (sickle cell anemia: ~40% of administered dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Children: ~7 L/hour (range: 1.6 to 22) (Ware 2011); Adults: ~7.5 L/hour (Rodriguez 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181008\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Droxia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $54.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $54.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (60): $58.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Hydrea Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $163.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Hydroxyurea Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $127.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181010\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biosupressin (HU);</li>\n      <li>Cytodrox (ID, JO, LK);</li>\n      <li>Droxamida (PE);</li>\n      <li>Hidrolid (AR);</li>\n      <li>Hidroxicarbamida (CL);</li>\n      <li>Hydab (PH);</li>\n      <li>Hydrea (AU, BB, BE, BG, BR, CL, CO, DK, EE, EG, ES, FI, GB, GR, HK, ID, IE, JP, KR, LT, LU, MT, MX, NL, NO, NZ, PK, RU, SE, TH, TW, UY, VN, ZA);</li>\n      <li>Hydrine (SG);</li>\n      <li>Hydronix (BD);</li>\n      <li>Hydroxycarbamid (PL);</li>\n      <li>Hydroxyurea medac (PL, SE);</li>\n      <li>Hytinon (VN);</li>\n      <li>Krabinex (PH);</li>\n      <li>Litalir (AT, CH, CZ, HN, HR, HU);</li>\n      <li>MPL Hi-Oxy (PH);</li>\n      <li>Neodrea (IN);</li>\n      <li>Onco-Carbide (IT);</li>\n      <li>Siklos (ES, FR, GB, TR);</li>\n      <li>Syrea (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alvarez O, Miller ST, Wang WC, et al, &ldquo;Effect of Hydroxyurea Treatment on Renal Function Parameters: Results From the Multi-Center Placebo-Controlled BABY HUG Clinical Trial for Infants With Sickle Cell Anemia,&rdquo; <i>Pediatr Blood Cancer</i>, 2012, 59(4):668-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22294512/pubmed\" target=\"_blank\" id=\"22294512\">22294512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. <i>Am J Hematol</i>. 2012;87(5):552-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22473827/pubmed\" target=\"_blank\" id=\"22473827\">22473827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i>. 2013;122(6):872-884.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/23803709/pubmed\" target=\"_blank\" id=\"23803709\">23803709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brawley OW, Cornelius LJ, Edwards LR, et al, &ldquo;National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease,&rdquo; <i>Ann Intern Med</i>, 2008, 148(12):932-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/18458271/pubmed\" target=\"_blank\" id=\"18458271\">18458271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burnett AK, Milligan D, Prentice AG, et al, &ldquo;A Comparison of Low-Dose Cytarabine and Hydroxyurea With or Without All-Trans Retinoic Acid for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment,&rdquo; <i>Cancer</i>, 2007, 109(6):1114-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/17315155/pubmed\" target=\"_blank\" id=\"17315155\">17315155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. <i>Blood</i>. 2012;120(7):1390-1397.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22613793/pubmed\" target=\"_blank\" id=\"22613793\">22613793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19880497\"></a>D&ouml;hner H, Estey EH, Amadori S, et al, &ldquo;Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet,&rdquo; <i>Blood</i>, 2010, 115(3):453-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/19880497/pubmed\" target=\"_blank\" id=\"19880497\">19880497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Droxia (hydroxyurea) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17264301\"></a>Finazzi G and Barbui T, &ldquo;How I Treat Patients With Polycythemia Vera,&rdquo; <i>Blood</i>, 2007, 109(12):5104-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/17264301/pubmed\" target=\"_blank\" id=\"17264301\">17264301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15254053\"></a>Garden AS, Harris J, Vokes EE, et al, &ldquo;Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck,&rdquo; <i>J Clin Oncol</i>, 2004, 22(14):2856-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/15254053/pubmed\" target=\"_blank\" id=\"15254053\">15254053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gisslinger H, Gotic M, Holowiecki J, et al, &ldquo;Anagrelide Compared With Hydroxyurea in WHO-Classified Essential Thrombocythemia: The ANAHYDRET Study, A Randomized Controlled Trial,&rdquo; <i>Blood,</i> 2013, 121(10):1720-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/23315161/pubmed\" target=\"_blank\" id=\"23315161\">23315161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"268956\"></a>Grund FM, Armitage JO, and Burns P, &ldquo;Hydroxyurea in the Prevention of the Effects of Leukostasis in Acute Leukemia,&rdquo; <i>Arch Intern Med</i>, 1977, 137(9):1246-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/268956/pubmed\" target=\"_blank\" id=\"268956\">268956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gwilt PR and Tracewell WG, &ldquo;Pharmacokinetics and Pharmacodynamics of Hydroxyurea,&quot; <i>Clin Pharmacokinet</i>, 1998, 34(5):347-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/9592619/pubmed\" target=\"_blank\" id=\"9592619\">9592619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hankins JS, Ware RE, Rogers ZR, et al, &ldquo;Long-Term Hydroxyurea Therapy for Infants With Sickle Cell Anemia: The HUSOFT Extension Study,&rdquo; <i>Blood</i>, 2005, 106(7):2269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/16172253/pubmed\" target=\"_blank\" id=\"16172253\">16172253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16000354\"></a>Harrison CN, Campbell PJ, Buck G, et al, &ldquo;Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia,&rdquo; <i>N Engl J Med</i>, 2005, 353(1):33-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/16000354/pubmed\" target=\"_blank\" id=\"16000354\">16000354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. <i>Pediatr Clin North Am</i>. 2008;55(2):483-501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/18381097/pubmed\" target=\"_blank\" id=\"18381097\">18381097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeney MM, Whorton MR, Howard TA, et al, &ldquo;Chemical and Functional Analysis of Hydroxyurea Oral Solutions,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2004, 26(3):179-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/15125610/pubmed\" target=\"_blank\" id=\"15125610\">15125610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. <i>Blood</i>. 1993;82(2):398-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/8329700/pubmed\" target=\"_blank\" id=\"8329700\">8329700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-Boluda JC1, Alvarez-Larr&aacute;n A, G&oacute;mez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. <i>Br J Haematol</i>. 2011;152(1):81-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/21083657/pubmed\" target=\"_blank\" id=\"21083657\">21083657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard LW and Kennedy LD, &ldquo;Hydroxyurea in the Treatment of Sickle-Cell Anemia,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(11):1393-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/9391697/pubmed\" target=\"_blank\" id=\"9391697\">9391697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydrea (hydroxyurea) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydrea (hydroxyurea) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kinney TR, Helms RW, O&rsquo;Branski EE, et al, &ldquo;Safety of Hydroxyurea in Children With Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial,&rdquo; <i>Blood</i>, 1999, 94(5):1550-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/10477679/pubmed\" target=\"_blank\" id=\"10477679\">10477679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &quot;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&quot; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16750989\"></a>Klion AD, Bochner BS, Gleich GJ, et al, &ldquo;Approaches to the Treatment of Hypereosinophilic Syndromes: A Workshop Summary Report,&rdquo; <i>J Allergy Clin Immunol</i>, 2006, 117(6):1292-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/16750989/pubmed\" target=\"_blank\" id=\"16750989\">16750989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar B, Saraswat A, and Kaur I, &ldquo;Rediscovering Hydroxyurea: Its Role in Recalcitrant Psoriasis,&rdquo; <i>Int J Dermatol</i>, 2001, 40(8):530-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/11703528/pubmed\" target=\"_blank\" id=\"11703528\">11703528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Longhurst HJ, and Pinching AJ, &ldquo;Pancreatitis Associated With Hydroxyurea in Combination With Didanosine,&rdquo; <i>Br Med J</i>, 2001, 322(7278):81.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGann PT, Flanagan JM, Howard TA, et al, &ldquo;Genotoxicity Associated With Hydroxyurea Exposure in Infants With Sickle Cell Anemia: Results from the BABY-HUG Phase III Clinical Trial,&rdquo; <i>Pediatr Blood Cancer</i>, 2012, 59(2):254-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22012708/pubmed\" target=\"_blank\" id=\"22012708\">22012708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maier-Redelsperger M, de Montalembert M, Flahault A, et al, &ldquo;Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients. The French Study Group on Sickle Cell Disease,&rdquo; <i>Blood</i>, 1998, 91(12):4472-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/9616141/pubmed\" target=\"_blank\" id=\"9616141\">9616141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9345019\"></a>Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. <i>Blood</i>. 1997;90(9):3370-3377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/9345019/pubmed\" target=\"_blank\" id=\"9345019\">9345019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda, MD: National Institutes of Health; 2014. <a href=\"http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines\" target=\"_blank\">http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines</a>. Accessed March 19, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11206012\"></a>Newton HB, Slivka MA, and Stevens C, &ldquo;Hydroxyurea Chemotherapy for Unresectable or Residual Meningioma,&rdquo; <i>J Neurooncol</i>, 2000, 49(2):165-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/11206012/pubmed\" target=\"_blank\" id=\"11206012\">11206012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ogbogu PU, Bochner BS, Butterfield JH, et al, &ldquo;Hypereosinophilic Syndrome: A Multicenter, Retrospective Analysis of Clinical Characteristics and Response to Therapy,&rdquo; <i>J Allergy Clin Immunol</i>, 2009, 124(6):1319-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/19910029/pubmed\" target=\"_blank\" id=\"19910029\">19910029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"677578\"></a>Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. <i>Ann Intern Med</i>. 1978;89(2):167-172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/677578/pubmed\" target=\"_blank\" id=\"677578\">677578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. <i>Haematologica</i>. 2005;90(2):261-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/15710584/pubmed\" target=\"_blank\" id=\"15710584\">15710584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restituto P, Mugueta C, Alegre E, et al, &ldquo;Analytical Interference of Hydroxyurea in the Determination of Urea, Uric Acid, and Lactic Acid,&rdquo; <i>Anal Biochem</i>, 2006, 357(1):147-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/16843426/pubmed\" target=\"_blank\" id=\"16843426\">16843426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez GI, Kuhn JG, Weiss GR, et al, &quot;A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea,&quot; <i>Blood</i>, 1998, 91(5):1533-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/9473217/pubmed\" target=\"_blank\" id=\"9473217\">9473217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rose PG, Ali S, Watkins E, et al, &ldquo;Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 2007, 25(19):2804-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/17502627/pubmed\" target=\"_blank\" id=\"17502627\">17502627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11922703\"></a>Rosenthal MA, Ashley DL, and Cher L. &ldquo;Treatment of High Risk or Recurrent Meningiomas With Hydroxyurea,&rdquo; <i>J Clin Neurosci</i>, 2002, 9(2):156-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/11922703/pubmed\" target=\"_blank\" id=\"11922703\">11922703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siklos (hydroxyurea) [prescribing information]. Bryn Mawr, PA: Medunik USA Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strouse JJ, Heeney MM. Hydroxyrea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. <i>Pediatr Blood Cancer</i>. 2012;59(2):365-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22517797/pubmed\" target=\"_blank\" id=\"22517797\">22517797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thornburg CD, Files BA, Luo Z, et al, &ldquo;Impact of Hydroxyurea on Clinical Events in the BABY HUG Trial,&rdquo; <i>Blood</i>, 2012, 120(22):4304-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/22915643/pubmed\" target=\"_blank\" id=\"22915643\">22915643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang WC, Ware RE, Miller ST, et al, &ldquo;Hydroxycarbamide in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BABY HUG),&rdquo; <i>Lancet</i>, 2011, 377(9778):1663-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/21571150/pubmed\" target=\"_blank\" id=\"21571150\">21571150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang WC, Wynn LW, Rogers ZR, et al, &ldquo;A Two-Year Pilot Trial of Hydroxyurea in Very Young Children With Sickle Cell Anemia,&rdquo; <i>J Pediatr</i>, 2001, 139(6):790-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/11743503/pubmed\" target=\"_blank\" id=\"11743503\">11743503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ware RE, Despotovic JM, Mortier NA, et al, &ldquo;Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children With Sickle Cell Anemia,&rdquo; <i>Blood</i>, 2011, 118(18):4985-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/21876119/pubmed\" target=\"_blank\" id=\"21876119\">21876119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. <i>Blood</i>. 2014;124(26):3850-3857.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/25287707/pubmed\" target=\"_blank\" id=\"25287707\">25287707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yan JH, Ataga K, Kaul S, et al, &ldquo;The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease,&rdquo; <i>J Clin Pharmacol</i>, 2005, 45(4):434-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/15778424/pubmed\" target=\"_blank\" id=\"15778424\">15778424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman SA, Schultz WH, Davis JS, et al, &ldquo;Sustained Long-Term Hematologic Efficacy of Hydroxyurea at Maximum Tolerated Dose in Children With Sickle Cell Disease,&rdquo; <i>Blood</i>, 2004, 103(6):2039-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information/abstract-text/14630791/pubmed\" target=\"_blank\" id=\"14630791\">14630791</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8543 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708910\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181021\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181022\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181060\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181025\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F181043\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F181026\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F181027\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5528419\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20500209\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F15598381\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F180998\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F180983\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50964559\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181002\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132627\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181001\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474843\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181070\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F180990\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181005\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F180987\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299494\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F180992\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181009\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2527156\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F3518430\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F180996\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F180986\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181004\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181008\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181010\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8543|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-patient-drug-information\" class=\"drug drug_patient\">Hydroxyurea (hydroxycarbamide): Patient drug information</a></li><li><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Hydroxyurea (hydroxycarbamide): Pediatric drug information</a></li></ul></div></div>","javascript":null}